Incyte Corporation INCY
123.20
(1.62)
(1.30%)
as of 29 Sep
- Market cap
- $26.1B
- P/E
- 15.4×
Follow INCY
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Incyte Corporation (INCY) Shares outstanding
Incyte Corporation's shares outstanding at the end of fiscal 2025 was $200.7M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $208.2M. Over the past ten years it has ranged from $187.3M (fiscal 2015) to $225.9M (fiscal 2023); the current reading is higher than 27% of that period. Incyte Corporation ranks 44th of 604 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Annual
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $200.7M | (4.67%) |
| FY2024 | $210.5M | (6.82%) |
| FY2023 | $225.9M | 0.88% |
| FY2022 | $224.0M | 0.85% |
| FY2021 | $222.1M | 1.83% |
| FY2020 | $218.1M | 0.19% |
| FY2019 | $217.7M | 0.94% |
| FY2018 | $215.6M | 5.40% |
| FY2017 | $204.6M | 5.39% |
| FY2016 | $194.1M | 3.64% |
Quarterly
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $208.2M | 0.67% |
| Mar 2026 | $206.8M | 3.05% |
| Dec 2025 | $200.7M | (0.36%) |
| Sep 2025 | $201.4M | 1.35% |
| 42 more quarters | Free account |
Against its own ten years
Low $187.3M
High $225.9M
Ten-year median
$215.6M
Current reading's percentile
27
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ROIV Roivant Sciences Ltd. compare | $720.8M |
| GMAB Genmab A/S Sponsored ADR compare | $617.1M |
| RPRX Royalty Pharma PLC compare | $556.9M |
| BNTX BioNTech SE Sponsored ADR compare | $253.3M |
| INSM Insmed, Inc. compare | $217.4M |
| INCY Incyte Corporation | $208.2M |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $138.3M |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $115.8M |
| JAZZ Jazz Pharmaceuticals PLC compare | $69.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- The full statement